Welcome to our dedicated page for Bausch + Lomb Corporation news (Ticker: BLCO), a resource for investors and traders seeking the latest updates and insights on Bausch + Lomb Corporation stock.
Bausch + Lomb Corporation is a global eye health company that develops, manufactures, and markets products for vision correction, eye care, and surgical treatment. The company operates through three business segments: Vision Care, Pharmaceuticals, and Surgical, serving markets in nearly 100 countries worldwide.
The Vision Care segment produces contact lenses across all wearing modalities, including daily disposable and frequently replaced lenses, along with lens care products, over-the-counter eye drops, and eye vitamins. The Pharmaceuticals segment offers prescription medications for conditions such as glaucoma, dry eye disease, eye inflammation, and retinal diseases. The Surgical segment provides intraocular lenses, phacoemulsification equipment, and surgical instruments used in cataract and retinal procedures.
With approximately 400 products in its portfolio, Bausch + Lomb serves eye care professionals, healthcare providers, and consumers through well-known brands including Biotrue, PreserVision, Lumify, XIIDRA, Vyzulta, Lotemax, and Ocuvite. The company maintains global research, development, manufacturing, and commercial operations to support its position in the international eye care products market.
News and developments related to Bausch + Lomb may include product launches, regulatory approvals for new medications or medical devices, clinical trial results, strategic partnerships, acquisitions of complementary businesses or technologies, manufacturing expansions, and updates on the company's financial performance across its three operating segments in various geographic markets.
Bausch + Lomb (NYSE: BLCO) announced a partnership with Glaucoma Research Foundation and The Glaucoma Foundation for Glaucoma Awareness Month in January 2026 to raise awareness and fund research into glaucoma, which affects about four million people in the U.S.
Key actions: Bausch + Lomb will launch its fifth annual fundraising challenge and match donations dollar-for-dollar up to $20,000 during January; it will also sponsor a month-long social media campaign spotlighting a glaucoma patient or advocate each day. All proceeds will support glaucoma research and education.
Bausch + Lomb (NYSE: BLCO) closed a refinancing under a Fourth Amendment to its credit agreement, establishing $2,802,125,000 of Replacement Term B loans to refinance outstanding term B loans due 2031 and 2028.
The Replacement Term Loans carry a 1.00% annual amortization with the first installment due June 30, 2026, and mature on January 15, 2031. The applicable margins are 3.75% over term SOFR or 2.75% over alternate base rate, representing a 50 bps reduction versus the prior 2031 tranche and a 25 bps reduction versus the 2028 tranche; the 2028 loans receive an effective five-plus year maturity extension to 2031.
Bausch + Lomb (NYSE: BLCO) announced that Chairman and CEO Brent Saunders, CFO Sam Eldessouky, and CMO & Head of R&D Yehia Hashad, MD will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, Jan. 12, 2026 at 1:30 p.m. PT (4:30 p.m. ET).
A live webcast and an audio archive will be available on the company Investor Relations website at http://ir.bausch.com/investors/events-presentations.
Bausch + Lomb (NYSE: BLCO) announced two board appointments: Eduardo C. Alfonso, MD and Steven H. Collis, effective Jan. 1, 2026. Following earlier August 2025 changes, the board will comprise 10 directors. Management says Alfonso brings deep ophthalmology expertise and Collis brings extensive CEO-level financial experience. The company framed the additions as support for accelerating strategy and pursuing significant opportunities ahead.
Bausch + Lomb (NYSE: BLCO) allocated a $2,802,125,000 tranche of Replacement Term B loans to refinance its outstanding term B loans due 2031 and 2028.
The Replacement Term Loans carry an anticipated margin of 3.75% over term SOFR or 2.75% over alternate base rate, representing a 0.50% reduction for the 2031 tranche and a 0.25% reduction for the 2028 tranche. The Replacement Term Loans will mature on January 15, 2031, extending the 2028 loans to the 2031 maturity date.
Closing is expected in Q1 2026, but completion on the described terms is not assured.
Bausch + Lomb (NYSE: BLCO) said Chairman and CEO Brent Saunders and EVP & CFO Sam Eldessouky will participate in a fireside chat at the 2025 Citi Global Healthcare Conference on Wednesday, Dec. 3, 2025 at 9:00 a.m. ET.
A live webcast and a post-event recording will be available on the company's Investor Relations events and presentations page: http://ir.bausch.com/investors/events-presentations.
Bausch + Lomb (NYSE: BLCO) outlined a three-year transformation and growth plan at its November 13, 2025 investor day at the New York Stock Exchange. Management targets 5–7% constant currency revenue CAGR through 2028, ~23% adjusted EBITDA (ex. Acq. IPR&D) margin in 2028, double-digit adjusted annual EPS growth from 2026–2028, ~50% adjusted cash flow to adjusted EBITDA conversion in 2028, and net leverage of ~3.5x by end of 2028, while reaffirming 2025 guidance. The company projects total peak sales of pipeline products of approximately $7 billion and highlighted multiple product launches across Consumer, Pharmaceuticals, Surgical, and Contact Lens businesses with anticipated launches spanning 2026–2031.
Bausch + Lomb (NYSE: BLCO) reports its ONE by ONE Recycling program has collected 691,180 pounds (about 114,037,136 units) of used contact lens, lens care and eye care materials in the U.S. to date, roughly equivalent to more than 2.2 million baseballs.
Shipments of 10+ pounds from registered practices trigger a $1 per pound donation to Optometry Giving Sight. The company also notes the Canada Every Contact Counts program has collected over 70,000 pounds since 2019.
Bausch + Lomb (NYSE: BLCO) will hold an Investor Day on Thursday, Nov. 13, 2025 at the New York Stock Exchange starting at 8:30 a.m. ET. CEO Brent Saunders will update the company's transformation and strategic outlook, and CFO Sam Eldessouky will present a three-year plan to drive sustainable, profitable growth.
The program emphasizes Bausch + Lomb's rebuilt product pipeline with R&D leaders, commercial presidents, and a panel of eye care professionals discussing clinical and standard-of-care implications. A live webcast and replay will be available via the company's Investor Relations site; replay is available until Nov. 27, 2025. Webcast registration and dial-in details are provided for attendees.
Bausch + Lomb (NYSE:BLCO) reported Q3 2025 revenue of $1.281B, up 7% reported and ~6% on a constant currency basis versus Q3 2024. Segment revenue: Vision Care $736M (+8%), Pharmaceuticals $330M (+8%), Surgical $215M (+4%).
GAAP net loss attributable was $28M; adjusted net income was $66M. Adjusted EBITDA (non-GAAP) and excluding acquired IPR&D were both $243M. Cash and equivalents were $332M. Updated full‑year 2025 guidance raised adjusted EBITDA ex‑IPR&D to $870M–$910M with revenue guidance unchanged at $5.05B–$5.15B.
FAQ
What is the current stock price of Bausch + Lomb Corporation (BLCO)?
What is the market cap of Bausch + Lomb Corporation (BLCO)?
